NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 87 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.33 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $153,135 | -6.6% | 184,500 | -21.2% | 0.00% | – |
Q1 2023 | $163,940 | +28.7% | 234,200 | -6.4% | 0.00% | – |
Q4 2022 | $127,403 | -49.4% | 250,300 | -36.5% | 0.00% | -100.0% |
Q3 2022 | $252,000 | -36.8% | 394,000 | +1.7% | 0.00% | 0.0% |
Q2 2022 | $399,000 | -26.5% | 387,600 | +34.1% | 0.00% | 0.0% |
Q1 2022 | $543,000 | -52.0% | 289,000 | +23.1% | 0.00% | -66.7% |
Q4 2021 | $1,131,000 | -10.4% | 234,700 | +34.4% | 0.00% | 0.0% |
Q3 2021 | $1,262,000 | +129.0% | 174,600 | +192.5% | 0.00% | +200.0% |
Q2 2021 | $551,000 | -44.2% | 59,700 | -25.7% | 0.00% | -66.7% |
Q1 2021 | $988,000 | -47.4% | 80,300 | -39.7% | 0.00% | -40.0% |
Q4 2020 | $1,877,000 | +96.3% | 133,100 | +67.0% | 0.01% | +66.7% |
Q3 2020 | $956,000 | +48.9% | 79,700 | +105.9% | 0.00% | +50.0% |
Q2 2020 | $642,000 | +184.1% | 38,700 | +94.5% | 0.00% | +100.0% |
Q1 2020 | $226,000 | -31.5% | 19,900 | -25.7% | 0.00% | 0.0% |
Q4 2019 | $330,000 | +202.8% | 26,800 | -30.2% | 0.00% | – |
Q3 2019 | $109,000 | – | 38,400 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Opaleye Management Inc. | 1,386,300 | $19,547,000 | 2.55% |
EcoR1 Capital, LLC | 3,122,704 | $44,030,000 | 2.37% |
Redmile Group, LLC | 4,131,869 | $58,259,000 | 0.70% |
Boxer Capital, LLC | 1,501,058 | $21,165,000 | 0.68% |
HighVista Strategies LLC | 69,727 | $983,000 | 0.63% |
Baker Brothers Advisors | 3,821,740 | $53,887,000 | 0.20% |
Highland Private Wealth Management | 93,998 | $1,326,000 | 0.12% |
Sio Capital Management, LLC | 38,312 | $540,000 | 0.11% |
Point72 Asset Management, L.P. | 1,195,725 | $16,860,000 | 0.08% |
Granahan Investment Management | 246,299 | $3,473,000 | 0.08% |